For more than twenty years, a monoclonal antibody has been used to protect infants against RSV.
Palivizumab, which is very expensive, has however been reserved since 1999 for children with a very high risk of severe forms of RSV bronchiolitis: premature babies born at less than 35 weeks and aged less than 6 months at the start of the seasonal epidemic, and children under 2 years of age who have required treatment for bronchopulmonary dysplasia within the last six months, or who have severe congenital heart disease.
It is delivered via a painful intramuscular injection every month during the winter season and specialists are therefore eagerly awaiting the results of a large European study with another monoclonal antibody, nirsevimab, which the European Medicines Agency has recommended. marketing authorization in September.
This study could lead to a marketing from 2023 of this treatment which only requires an injection...
This article is for subscribers only.
You have 63% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
